Cantor Fitzgerald raised the firm’s price target on MiMedx (MDXG) to $12 from $11 and keeps an Overweight rating on the shares following the company reporting a Q2 revenue beat and raising 2025 revenue guidance. Given the firm’s belief that MiMedx and Organogenesis (ORGO) are positioned to take market share in 2026 and represent undervalued opportunities, it would be buyers amid the share’s strength.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG: